ClinicalTrials.gg
RecruitingNCT07942571Updated Nov 17, 2026

Olfactory Function in Patients With Sinonasal Diseases: A Multicenter Observational Study

An observational study in Chronic Rhinosinusitis, Sinonasal Diseases and Olfactory Dysfunction, sponsored by University of Brasilia. Recruiting at 12 sites in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Brasilia · Observational

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
3,800
Ages
18 Years and older
Sex
All
01

Study summary

This multicenter, cross-sectional observational study aims to characterize olfactory function in patients with sinonasal diseases and investigate its associations with disease severity, clinical characteristics, and inflammatory markers. Olfactory function will be assessed using the MultiScent-20 digital odor identification test. Additional assessments will include sinonasal symptom severity, quality of life, endoscopic and radiological findings, and clinical and laboratory markers suggestive of type 2 inflammation. Healthy volunteers without olfactory complaints will serve as a comparison group. The study is expected to enroll 3,800 participants across participating centers in Brazil.

Read the detailed description

This is a multicenter, cross-sectional observational study conducted in Brazilian outpatient otolaryngology settings. The study aims to investigate olfactory function in patients with chronic rhinosinusitis and other sinonasal diseases and to explore its associations with clinical manifestations, disease severity, and inflammatory characteristics.

Olfactory function will be objectively assessed using the MultiScent-20 digital odor identification test, which provides a score ranging from 0 to 20, with higher scores indicating better olfactory performance. Participants will undergo a single study assessment.

Clinical data will include sinonasal symptoms, SNOT-22 scores, visual analog scale ratings, nasal polyp scores, previous sinonasal surgeries, relevant comorbidities, and alcohol intolerance. Laboratory, histopathological, and imaging findings obtained during routine clinical care within the predefined eligibility window will be collected when available.

Criteria suggestive of type 2 inflammation will be evaluated using predefined clinical and laboratory characteristics. Missing clinical or laboratory information will not constitute an exclusion criterion. Analyses involving individual variables will include participants with the corresponding available data, whereas the total count of type 2 inflammatory criteria will be calculated only when all eight criteria have been assessed.

A comparison group of healthy volunteers without olfactory complaints will also be included. No therapeutic intervention will be administered as part of this observational study.

02

Conditions studied

  • Chronic Rhinosinusitis
  • Sinonasal Diseases
  • Olfactory Dysfunction

Browse trials for

03

In context

Rhinosinusitis

252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.

This study's planned enrollment of 3,800 is above the median of 123 across 62 observational studies indexed under Rhinosinusitis.

Browse Rhinosinusitis studies →

Lead sponsor

University of Brasilia is the lead sponsor of 68 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults aged 18 years or older with chronic rhinosinusitis or other sinonasal diseases and healthy volunteers without olfactory complaints, recruited at participating outpatient centers in Brazil.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged 18 years or older. Patients with chronic rhinosinusitis or other sinonasal diseases, or healthy volunteers without olfactory complaints participating in the comparison group.

Ability to understand and complete the study assessments.

Exclusion criteria

Exclusion Criteria:

Illiteracy. Respiratory tract infection within the preceding seven days. Sinonasal surgery within the preceding six months. History of severe head trauma. Diagnosis of a neurodegenerative disease.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
3,800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Sinonasal Disease Participants

    Adults with chronic rhinosinusitis or other sinonasal diseases.

  • Healthy Comparison Participants

    Healthy adults without olfactory complaints.

06

What researchers measure

Primary outcomes

  1. MultiScent-20 odor identification score

    Total number of correctly identified odors on the 20-item MultiScent-20 digital odor identification test. Scores range from 0 to 20; higher scores indicate better odor identification performance.

    Time frame: Once at enrollment (cross-sectional assessment).

Secondary outcomes

  1. Sinonasal Outcome Test-22 (SNOT-22) total score

    Patient-reported sinonasal symptom burden assessed using the 22-item SNOT-22 questionnaire. Total scores range from 0 to 110; higher scores indicate greater symptom burden.

    Time frame: Once at enrollment (cross-sectional assessment).

  2. Severity of four sinonasal symptoms on visual analog scales

    Severity will be assessed separately for nasal obstruction, rhinorrhea, facial pain or pressure, and olfactory dysfunction using four individual visual analog scales (VAS). Each score ranges from 0 (no symptoms) to 10 (maximum symptom intensity). Each symptom score will be analyzed in relation to the MultiScent-20 odor identification score. No combined VAS total score is prespecified.

    Time frame: Once at enrollment (cross-sectional assessment).

  3. Nasal Polyp Score (NPS)

    Endoscopic nasal polyp burden assessed using the Nasal Polyp Score, ranging from 0 to 8; higher scores indicate greater polyp burden. Applicable to participants with available endoscopic assessment.

    Time frame: At enrollment, using available routine clinical assessment.

  4. Lund-Mackay computed tomography score

    Extent of sinonasal opacification on computed tomography evaluated using the Lund-Mackay scoring system (total score 0-24; higher scores indicate more extensive radiologic disease). Assessed when routine-care imaging is available.

    Time frame: At enrollment; CT performed within the 12 months preceding enrollment, if available.

  5. Peripheral blood eosinophil count

    Absolute peripheral blood eosinophil count obtained from available routine-care laboratory testing.

    Time frame: At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.

  6. Total serum immunoglobulin E (IgE)

    Total serum IgE concentration obtained from available routine-care laboratory testing.

    Time frame: At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.

  7. Number of clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis

    Count of predefined clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis, according to the guideline for use of biologics in chronic rhinosinusitis with nasal polyps cited in the study protocol. Clinical criteria: symptom onset between ages 30 and 50 years; marked improvement in olfaction following oral corticosteroid use; adult-onset asthma; aspirin or nonsteroidal anti-inflammatory drug intolerance; and bilateral nasal polyps associated with thick allergic- or eosinophilic-appearing nasal mucus, preferably confirmed by nasal endoscopy. Biomarker criteria: tissue eosinophils ≥10 cells/high-power field; blood eosinophils ≥250 cells/µL; or total serum IgE ≥100 IU/mL. The total number of criteria suggestive of type 2 inflammation will be calculated only for participants with complete data on all eight clinical and laboratory criteria. The count ranges from 0 to 8 and equals the number of positive criteria.

    Time frame: Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.

  8. Presence of selected comorbidities

    Presence or absence of relevant comorbidities, including asthma and aspirin-exacerbated respiratory disease (AERD), recorded from clinical history.

    Time frame: Once at enrollment (cross-sectional assessment).

  9. Number of previous sinonasal surgeries

    The number of previous sinonasal surgeries will be recorded for each participant.

    Time frame: Once at enrollment (cross-sectional assessment).

  10. Alcohol intolerance

    Alcohol intolerance will be assessed as a binary variable (yes/no), based on self-reported nasal symptoms following the consumption of alcoholic beverages.

    Time frame: Once at enrollment (cross-sectional assessment).

07

Study locations

12 of 12 sites recruiting
  • Hospital Universitário Professor Edgard Santos (HUPES)
    Salvador, Estado de Bahia, Brazil
    Recruiting
  • Hospital Universitário de Brasília (HUB)
    Brasília, Federal District, Brazil
    Recruiting
  • Hospital das Clínicas da UFG
    Goiânia, Goiás, Brazil
    Recruiting
  • Hospital IPO - sede Água Verde
    Curitiba, Paraná, Brazil
    Recruiting
  • Hospital das Clínicas da UFPE
    Recife, Pernambuco, Brazil
    Recruiting
  • Hospital Getúlio Vargas (HGV)
    Teresina, Piauí, Brazil
    Recruiting
  • Hospital Universitário Pedro Ernesto
    Rio de Janeiro, Rio de Janeiro, Brazil
    Recruiting
  • Hospital Universitário Canoas
    Canoas, Rio Grande do Sul, Brazil
    Recruiting
  • Hospital de Clínicas de Porto Alegre (HCPA)
    Porto Alegre, Rio Grande do Sul, Brazil
    Recruiting
  • Hospital das Clínicas da FMRP-USP - Campus
    Ribeirão Preto, São Paulo, Brazil
    Recruiting
  • Hospital das Clínicas da FMUSP
    São Paulo, São Paulo, Brazil
    Recruiting
  • Hospital São Paulo - Hospital Universitário da UNIFESP
    São Paulo, São Paulo, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Nov 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartActual
Mar 1, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942571
Lead sponsor
University of Brasilia
Responsible party
Gustavo Subtil Magalhães Freire (Principal Investigator, University of Brasilia) — Principal investigator
First posted
Nov 17, 2026
Start date
Mar 1, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Gustavo Subtil M. Freire, MSc
Contact
gustavo.freire@ebserh.gov.br
+55 61 2028-5000
Gustavo Subtil M. Freire
principal investigator · University of Brasilia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion